Whole-Genome Sequencing vs. Targeted Panels in Rare Disease Diagnosis: Cost-Effectiveness and Diagnostic Yield
Clinicians face tough choices in rare disease diagnosis. They often select between targeted gene panels and whole-genome sequencing (WGS). Both methods help identify genetic causes. However, they differ in scope, cost, and success rates.
Targeted panels focus on specific genes. Doctors choose these panels for known disease-associated genes. This approach keeps costs low. It also delivers results quickly. In many cases, panels solve 20–35% of rare disease cases. Moreover, they work well when the clinical picture points to a particular disorder.
Whole-genome sequencing reads the entire DNA. It captures coding and non-coding regions. As a result, WGS detects novel variants. It also finds structural changes and deep intronic mutations. Studies show WGS achieves higher diagnostic yields. Recent data report 40–60% success rates in undiagnosed rare diseases. Additionally, WGS often ends the diagnostic odyssey faster for complex cases.
Cost remains a key factor. Targeted panels cost less upfront. Prices usually range from $1,000 to $3,000 per test. In contrast, WGS prices have dropped sharply. Today, clinical WGS often costs $2,000 to $6,000. However, the total expense includes interpretation time. Complex analysis raises the real cost for WGS.
Researchers compare cost-effectiveness carefully. Panels prove more efficient for straightforward cases. They offer good yield at lower cost. On the other hand, WGS becomes cost-effective in broader scenarios. It saves money when multiple panels would otherwise be ordered. Furthermore, WGS reduces the need for additional tests over time.
Health systems weigh these trade-offs. Some start with panels and escalate to WGS if needed. Others adopt WGS as first-line testing for severe or heterogeneous diseases. This strategy improves outcomes. It also cuts long-term healthcare spending.
In summary, targeted panels suit focused diagnoses. They remain affordable and fast. Whole-genome sequencing excels in unsolved cases. It provides higher yield despite higher initial costs. Both tools play vital roles. The best choice depends on the patient’s clinical features and available resources. Ongoing price reductions continue to favor broader genomic approaches.